PROTAC EZH2 Degrader-35 

PROTAC EZH2 Degrader-35 (compound U3i (44)) is a PROTAC protein degrader targeting EZH2 with a human EZH2 K_a of 16.19 nM. PROTAC EZH2 Degrader-35 exhibits antiproliferative activity in triple-negative breast cancer cells and minimal cytotoxicity in normal human epithelial, hepatic, renal cells.PROTAC EZH2 Degrader-35 can be used for the research of triple-negative breast cancer^[1]. (Pink: EZH2 ligand (HY-181393); Blue: Cereblon ligand (HY-10984); Black: linker).

PROTAC EZH2 Degrader-35 binds to the PRC2 complex with high affinity, as shown by a K_d of 16.19 nM^[1].
PROTAC EZH2 Degrader-35 potently inhibits the proliferation of MDA-MB-231 and MDA-MB-468 triple-negative breast cancer cells, with IC₅₀ values of 0.57 μM and 0.38 μM, respectively^[1].
PROTAC EZH2 Degrader-35 induces CRBN- and proteasome-dependent degradation of PRC2 complex components, reduces oncogenic histone modifications, triggers mitochondrial dysfunction and apoptosis in cancer cells, and shows minimal toxicity to normal human cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1270.48

C₆₆H₈₇N₁₃O₁₃

3034875-56-1

O=C(C1=CC(C2=CC=C(N3CCN(CC3)C(CCCCCCCCC4=CN(CCOCCOCCOCCOCCOCCOCCNC5=CC=CC(C(N6C7C(NC(CC7)=O)=O)=O)=C5C6=O)N=N4)=O)N=C2)=CC8=C1C=NN8C(C)C)NCC9=C(C)C=C(C)NC9=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. S Abulkhair H, et al. Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives. RSC Adv. 2026;16(4):3034-3056. Published 2026 Jan 14.  [Content Brief]